Chargement en cours...
Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial
BACKGROUND: Clozapine causes significant metabolic disturbances including obesity and type 2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute to aetiology of clozapine-associated metabolic dysregulation suggests a potential therapeutic role for GLP-1 agonists. ME...
Enregistré dans:
| Publié dans: | BJPsych Open |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Royal College of Psychiatrists
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4998934/ https://ncbi.nlm.nih.gov/pubmed/27703725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1192/bjpo.bp.115.001073 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|